• Publications
  • Influence
Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.
BACKGROUND & AIMS Therapy for polycystic liver is invasive, expensive, and has disappointing long-term results. Treatment with somatostatin analogues slowed kidney growth in patients with polycysticExpand
  • 213
  • 8
  • PDF
Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases
Background and aim: Isolated polycystic liver disease (PCLD) is characterized by the presence of multiple cysts in the liver in the absence of polycystic kidneys. The clinical profile of PCLD isExpand
  • 94
  • 7
Carbohydrate antigen 19‐9 is extremely elevated in polycystic liver disease
Background/Aims: Carbohydrate antigen 19‐9 (CA19‐9) is used as a biomarker to differentiate benign from malignant gastrointestinal disorders. We examined the value of CA19‐9 measurement in polycysticExpand
  • 59
  • 2
The long‐term outcome of patients with polycystic liver disease treated with lanreotide
Aliment Pharmacol Ther 2012; 35: 266–274
  • 80
  • 1
Excellent survival after liver transplantation for isolated polycystic liver disease: an European Liver Transplant Registry study
Patients with end‐stage isolated polycystic liver disease (PCLD) suffer from incapacitating symptoms because of very large liver volumes. Liver transplantation (LT) is the only curative option. ThisExpand
  • 53
  • 1
Somatostatin analogues reduce liver volume in polycystic liver disease
Polycystic livers occur in the setting of two inherited conditions: (1) autosomal dominant polycystic kidney disease (ADPKD), also characterised by progressive development of renal cysts resulting inExpand
  • 50
  • 1
Aspiration–sclerotherapy Results in Effective Control of Liver Volume in Patients with Liver Cysts
Purpose To study the extent to which aspiration–sclerotherapy reduces liver volume and whether this therapy results in relief of symptoms. Results Four patients, group I, with isolated large liverExpand
  • 47
  • 1
  • PDF
Hepatic and renal manifestations in autosomal dominant polycystic kidney disease: a dichotomy of two ends of a spectrum.
Autosomal dominant polycystic kidney disease (ADPKD) is a multisystem disorder. It is the most common genetic cause of end-stage renal disease. One frequent extra-renal manifestation is hepatic cystExpand
  • 17
  • 1
  • PDF
Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation.
van Keimpema, Loes Drenth, Joost P H Comment Letter United States Ann Surg. 2011 Feb;253(2):419; author reply 420.
  • 44
  • 1
Treatment of polycystic liver disease
The diagnosis of polycystic liver is based on the finding of numerous fluid-filled cysts scattered throughout the liver parenchyma. Although of biliary epithelial origin, the cysts have no connectionExpand
  • 28
  • 1